SEARCH:      Monitor Keywords |  Custom RSS

Organic compounds -- part of the class 532-570 series July category listing 07/11

20110184168 - Long wavelength thiol-reactive fluorophores: Reactive fluorescent dyes compositions and methods of using same are disclosed. Squaraine nucleus, Nile Red nucleus, benzodioxazole nucleus, coumarin nucleus or aza coumarin nucleus dyes are disclosed having thiol-reactive groups. Squaraine nucleus, Nile Red nucleus, benzodioxazole nucleus, coumarin nucleus or aza coumarin nucleus dyes are disclosed that exhibit a fluorescence... Agent: Becton, Dickinson And Company

20110184169 - Process of isolating enantiomer component from enantiomer mixtures by particle-size-controlled crystallization: The present invention discloses a process for isolating enantiomer components from a mixture of enantiomers through particle-size-controlled crystallization, comprising the steps of: (a) forming a solution of a mixture of enantiomers (R) and (S) in a solvent in the absence of any further additives or agents; (b) seeding the solution... Agent:

20110184170 - Metallic compound and organic electroluminescence device comprising the same: The present invention relates to an organic electroluminescence device containing a light emitting metallic compound of Chemical Formula 1. In the Chemical Formula 1, M is selected from Ir, Pt, Rh, Re, and Os, and m is 2, provided that m is 1 when M is Pt.... Agent: Industry-university Cooperation Foundation, Hanyang University

20110184171 - Acylation of hindered amines and functionalized bis-peptides obtained thereby: Functionalized bis-peptides as well as other amide-containing compounds are obtained by acylation of hindered amines. The functionalized bis-peptides are useful as shape-programmable nanostructures that are immune to denaturation and that contain arrays of functional groups having designed catalytic, protein-binding and/or sensor capabilities.... Agent: University Of Pittsburgh Of The Commonwealth System Of Higher Education

20110184172 - Process for the preparation of methyl ester of rosuvastatin: Process for the preparation of enantiomerically pure methyl ester of rosuvastatin has been developed, wherein the crude methyl ester ester is first purified by preparative chromatography, followed by crystallization.... Agent: Lek Pharmaceuticals D.d.

20110184173 - Pyripyropene derivatives having an acat2-inhibiting activity: The present invention is a compound having the general formula (I), (II), or (III) or a pharmacologically acceptable salt, solvate, or hydrate thereof, and a pharmaceutical composition containing such a compound, or its pharmacologically acceptable ester, or other pharmacologically acceptable derivative thereof as an active ingredient. The compound has an... Agent: The Kitasato Institute

20110184174 - Processes for the synthesis of levocetirizine and intermediates for use therein: wherein R is Cl, Br, NO2, OH or OR′, and R′ is alkyl, and its use in the synthesis of levocetirizine, including its use in the synthesis of (−)-1-[(4-chlorophenyl)-phenylmethyl]piperazine, an intermediate useful in the synthesis of levocetirizine. The present invention also provides compounds (II) and (III) which are useful in... Agent: Cipla Limited

20110178293 - Novel oxazolidinone derivatives with cyclic amidoxime or cyclic amidrazone and pharmaceutical compositions thereof: Disclosed is a novel oxazolidinone derivative, particularly a novel oxazolidinone compound with a cyclic amidoxime or cyclic amidrazone group. Also disclosed is a pharmaceutical antibiotic composition including a novel oxazolidinone derivative, a prodrug thereof, a hydrate thereof, a solvate thereof, an isomer thereof or a pharmaceutically acceptable salt thereof as... Agent: Legochem Bioscience Ltd.

20110178294 - Novel carboxylic acid derivatives, their preparation and use: s

20110178296 - Process for preparing pyrimidine propenaldehyde: The present invention relates to an improved process for preparing (2E)-3-[4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N-methylsulfonylamino)pyrimidin-5-yl]-propenal of formula (I), which is an useful intermediate in the preparation of Rosuvastatin.... Agent:

20110178295 - Synthesis of statins: The process for the synthesis of statins featuring the use of an early intermediate (4R,6S)-6-(dialkoxymethyl)tetrahydro-2H-pyran-2,4-diol which already possesses the desired stereochemistry corresponding to the final statin.... Agent: Lek Pharmaceuticals D.d.

20110178297 - Process for the synthesis of halogenated cyclic compounds: which comprises (a) adding an acid halide of formula R1—C (O)—X, to a vinyl ether of formula (II): CH2═CH—OR2, to produce an addition product, and (b) reacting the addition product with a compound of formula (III): Y-A-Z; wherein R1 is a halogenated alkyl group; wherein X is fluorine, chlorine, or... Agent: Solvay Sa

20110178298 - Reduction of 5-(aryl-diazenyl)-4,6-dihalo-pyrimidine: Method of synthesizing a compound of formula (I), wherein R1, R2 are, independently, chloro or fluoro, and wherein R3 is H, alkyl, aralkyl or is an alkylether or alkylthioether comprising the steps of firstly reducing a diazeny compound of formula (II) non-catalytically or with a catalytic amount of an homogenous... Agent:

20110178299 - Optically active difluoromethanesulfonanilide derivative and herbicide: t

20110178300 - Novel synthesis of substituted 4-amino-pyrimidines: The present invention is directed to a process for the manufacture of compounds of formula IV wherein R1 is an amino protecting group, and R2 is hydrogen or C1-10 alkyl, comprising a) reacting a compound of formula Ia, wherein M+ is a cation, preferably selected from the group consisting of... Agent:

20110178301 - Heterocyclical chromophore architectures: e

20110178302 - Nucleophilic fluorination of aromatic compounds: Iodylbenzene derivatives substituted with electron donating as well as electron withdrawing groups on the aromatic ring are used as precursors in aromatic nucleophilic substitution reactions. The iodyl group (IO2) is regiospecifically substituted by nucleophilic fluoride to provide the corresponding fluoroaryl derivatives. No-carrier-added [F-18]fluoride ion derived from anhydrous [F-18](F/Kryptofix, [F-18]CsF or... Agent: The Regents Of The University Of California

20110172417 - Heterogeneous copper nanocatalyst and manufacturing methods thereof: This invention relates to a heterogeneous copper nanocatalyst composed of copper nanoparticles immobilized on a boehmite support, a method of preparing the same, and the use thereof. The copper nanocatalyst composed of the copper nanoparticles supported on boehmite exhibits excellent performance in a Huisgen cycloaddition reaction and an A3 coupling... Agent: Postech Academy-industry Foundation

20110172418 - Antisense restenosis composition and method: The present invention provides an improved method for reducing the risk or severity of restenosis following cardiac angioplasty. The method includes administering to a target vessel region, a morpholino antisense compound having a phosphorus-containing backbone linkages, and spanning the start codon of a human c-myc mRNA. Also disclosed are novel... Agent: Avi Biopharma, Inc.

20110172419 - Process for the synthesis of cyclic carbamates: e

20110172420 - Sulfonamide derivatives of polycyclic dyes used for analytical applications: The invention concerns the production of quinoline compounds containing sulfonic acid groups, the said quinoline compounds and their conversion into dyes containing sulfonic acid groups. The dyes according to the invention are used especially to label analytes, for example to label biomolecules.... Agent: Atto-tec Gmbh

20110172421 - N-(alpha-aromatic group-substituted-2-nitro-4,5-dialkoxybenzyloxycarbonyl)amine compound and process for producing the same: e

20110172422 - Methods of making pharmacokinetically improved compounds comprising functional residues or groups and pharmaceutical compositions comprising said compounds: The present invention relates to methods of modulating the pharmacokinetic and/or pharmacodynamic properties of a compound by attaching at least one functional unit or group to the compound, thereby improving its non-specific binding characteristics and/or pharmacokinetic properties. Compounds comprising at least one functional residue are provided, as are pharmaceutical compositions... Agent: Surface Logix, Inc.

20110172423 - Cyclic phosphazene compounds and use thereof in organic light emitting diodes: An organic light-emitting diode comprising at least one cyclic phosphazene compound, a light-emitting layer formed from at least one matrix material and at least one emitter material, wherein the at least one matrix material comprises at least one cyclic phosphazene compound, the use of cyclic phosphazene compounds in organic light-emitting... Agent: Osram Opto Semiconductors Gmbh

20110172424 - New crystalline forms of pemetrexed diacid, and preparations thereof: Three new crystalline forms of pemetrexed diacid, preparation methods and uses thereof are disclosed. These preparation processes are simple and have better practicality.... Agent: Chongqing Pharmaceutical Research Institute Co., Ltd.

20110172425 - Novel water based process for the preparation of substituted diphenylmethyl piperazines: wherein X1 and X2 represent independently a hydrogen, a halogen, a straight or branched chain lower alkyl, alkoxy or a hydroxyl radical and R is selected from groups such as acyl, alkyl, alkenyl, aralalkyl, aralalkenyl aralkyl, and aralalkenyl or aralkenyl hydroxyalkyl, aryloxyalkyl, alkoxyalkyl, aminoalkyl or its derivative comprising, reacting a... Agent: Calyx Chemicals And Pharmaceuticals Pvt. Ltd.

20110166344 - 5,6-dihydro-1h-pyridin-2-one compounds: P

20110166345 - Thiazolyl-pyrazolopyrimidine compounds as synthetic intermediates and related synthetic processes:

20110166346 - Novel napthalimide-benzimidazole hybrids as potential antitumor agents and process for the preparation thereof: The present invention provides the compounds of general formula 5 and 9 useful as potential antitumour agents against human cancer cell lines. The present invention further provides the process for preparation of napthalimide-benzimidazole hybrids of general formula 5 and 9, n-1-2, R=n-methylpiperazine or morpholine (Formula 9), wherein: n=2-3, m=2-3 and... Agent:

20110166347 - Process for preparation of mycophenolic acid, its salt and ester derivatives: The present invention discloses an isolation and purification process for mycophenolic acid obtained from the fermentation process. Invention further discloses preparation of sodium salt of mycophenolic acid and mycophenolate mofetil from mycophenolic acid.... Agent: Ipca Laboratories Ltd.

20110166348 - Novel salt of morpholine derivative: Provided are an acid addition salt of (+)-2-[(inden-7-yloxy)methyl]morpholine (compound A) and a novel crystal thereof, which are for use as a medicament or a drug substance, and which has high storage stability, particularly high stability against humidity and light. An acid addition salt of the compound A with an acid... Agent: Astellas Pharma Inc.

20110166349 - Gold catalyzed hydroamination of alkynes and allenes: Methods are provided for the catalytic hydroamination of compounds having an alkyne or allene functional group, in which the compound is contacted with ammonia or an amine in the presence of a catalytic amount of a gold complex under conditions sufficient for hydroamination to occur.... Agent: The Regents Of The University Of California

20110166350 - Novel crystal forms of 4-(2-aminopyridin-4-yl)-3-(4-fluorophenyl)-1-(1,4,5,6-tetrahydro-6-oxopyridazin-3-yl)-1h-pyrazole methanesulfonate and methods for their preparation: t

20110166351 - Method for preparing 5-[2-(methylthio)ethoxy]pyrimidine-2-amine: A novel method for preparing 5-[2-(methylthio)ethoxy]pyrimidin-2-amine useful as a regent or raw material for manufacture of medicaments, agricultural chemicals, and industrial products, which comprises alkanoylating the amino group of a 2-amino-4-alkoxypyrimidine, then converting the resultant into a 4-hydroxypyrimidine compound by a treatment with anhydrous aluminum chloride, further etherifying the 4-hydroxypyrimidine... Agent: Kowa Company, Ltd.

20110166352 - Process for making sterile aripiprazole of desired mean particle size: A process is provided for making sterile aripiprazole having an average particle size less than 100 microns but preferably greater than 25 microns employing an impinging jet crystallization procedure. The resulting bulk aripiprazole of desired particle size may be used to form a sterile freeze-dried aripiprazole formulation, which upon constitution... Agent: Bristol-myers Squibb Company